(S)-N-[3-(3-hydroxymethyl-1,4,5,6-tetrahydro-1,2-diaza-benzo[e]azulen-8-yl)-2-oxo-oxazolidin-5-ylmethyl]-acetamide | 741723-34-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑烷类
• 英文名称: (S)-N-[3-(3-hydroxymethyl-1,4,5,6-tetrahydro-1,2-diaza-benzo[e]azulen-8-yl)-2-oxo-oxazolidin-5-ylmethyl]-acetamide
• 英文别名: N-[[(5S)-3-[5-(hydroxymethyl)-3,4-diazatricyclo[8.4.0.02,6]tetradeca-1(10),2,5,11,13-pentaen-12-yl]-2-oxo-1,3-oxazolidin-5-yl]methyl]acetamide
• CAS: 741723-34-2
• 化学式: C₁₉H₂₂N₄O₄
• 分子量: 370.408
• InChiKey: PEIQEWKQKLINHV-AWEZNQCLSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  27
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  108
• 氢给体数：
  3
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  (S)-N-[3-(3-benzyloxymethyl-1,4,5,6-tetrahydro-1,2-diaza-benzo[e]azulen-8-yl)-2-oxo-oxazolidin-5-ylmethyl]-acetamide 在 5%-palladium/activated carbon 氢气 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 反应 82.0h， 以51%的产率得到(S)-N-[3-(3-hydroxymethyl-1,4,5,6-tetrahydro-1,2-diaza-benzo[e]azulen-8-yl)-2-oxo-oxazolidin-5-ylmethyl]-acetamide
  参考文献：
  名称：

  [EN] ANTIBACTERIAL AGENTS
  [FR] AGENTS ANTIBACTERIENS

  摘要：

  公开号：

  WO2004069832A3

文献信息

• Antibacterial agents
  申请人：Boyer Earl Frederick

  公开号：US20050288273A1

  公开（公告）日：2005-12-29

  Compounds of formula I and methods for their preparation are disclosed. Further disclosed are methods of making biologically active compounds of formula I as well as pharmaceutically acceptable compositions comprising compounds of formula I. Compounds of formula I as disclosed herein can be used in a variety of applications including use as antibacterial agents.

  本文披露了I式化合物及其制备方法。此外，还披露了制备具有生物活性的I式化合物的方法，以及包含I式化合物的药学上可接受的组合物的方法。本文所披露的I式化合物可以用于多种应用，包括用作抗菌剂。
• Bicyclic amides
  申请人：Castonguay A. Laurie

  公开号：US20050203112A1

  公开（公告）日：2005-09-15

  Novel compounds of the structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, and cirrhosis of the liver.

  结构式（I）的新化合物为大麻素-1（CB1）受体的拮抗剂和/或反向激动剂，并可用于治疗、预防和抑制由CB1受体介导的疾病。本发明的化合物可用作中枢作用药物，治疗精神病、记忆障碍、认知障碍、偏头痛、神经病、神经炎性疾病（包括多发性硬化症和吉兰-巴雷综合征）以及病毒性脑炎、脑血管意外和头部创伤的炎症后遗症、焦虑症、压力、癫痫、帕金森病、运动障碍和精神分裂症。该化合物还可用于治疗物质滥用障碍、肥胖症或进食障碍以及哮喘、便秘、慢性肠假性梗阻和肝硬化。
• ANTIBACTERIAL AGENTS
  申请人：Warner-Lambert Company LLC

  公开号：EP1594865A2

  公开（公告）日：2005-11-16
• [EN] ANTIBACTERIAL AGENTS<br/>[FR] AGENTS ANTIBACTERIENS
  申请人：WARNER LAMBERT CO

  公开号：WO2004069832A3

  公开（公告）日：2004-10-21